Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00926315|
Recruitment Status : Unknown
Verified October 2012 by Eduardo Carneiro de Lyra, University of Sao Paulo General Hospital.
Recruitment status was: Active, not recruiting
First Posted : June 23, 2009
Last Update Posted : November 1, 2012
|Condition or disease||Intervention/treatment||Phase|
|Breast Neoplasms Postmenopausal Disorder||Drug: calcitriol Drug: Calcitriol||Not Applicable|
Women affected by breast cancer present lower 1,25(OH)2D3 or 25(OH)D3 serum levels than unaffected ones. Calcitriol supplementation may be indicated to post-menopausal women to reduce bone loss. Vitamin D has antiproliferative effects in breast cancer cell lines and breast cancer xenografts.
Post-menopausal breast cancer patients will be prescribed calcitriol supplementation, in doses indicated to prevent osteoporosis, while they are submitted to biopsy, staging exams and have their breast surgery scheduled (approximately one month). Tumor dimension and proliferation rate (as determined by Ki67 expression), 25(OH)D3 and/or 1,25(OH)2D3 serum concentration, will be evaluated before and after calcitriol supplementation. Tumor gene expression will be evaluated in samples collected before and after supplementation to analyze the differential profile.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Influence of Vitamin D on Gene Expression Profile of Breast Cancer Samples From Post-menopausal Patients|
|Study Start Date :||July 2007|
|Estimated Primary Completion Date :||June 2013|
|Estimated Study Completion Date :||December 2013|
calcitriol supplementation (0.25 mcg 2x/d)
Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
Other Name: Rocaltrol
calcitriol 0.25 mcg PO bid
Other Name: Rocaltrol
- Tumor dimension and proliferation evaluated by ultrasound and Ki67 expression; Tumor gene expression profile [ Time Frame: 30 days ]
- Follow-up for 5 years [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00926315
|Instituto Brasileiro de Controle do Câncer - IBCC|
|São Paulo, SP, Brazil, 03102-002|
|Study Chair:||Maria Aparecida A Koike Folgueira, MD,PhD||Faculdade de Medicina - Universidade de São Paulo|
|Principal Investigator:||Eduardo Carneiro de Lyra, MD, PhD||Instituto Brasileiro de Controle do Cancer|
|Principal Investigator:||Yuri N Urata, MSc||Faculdade de Medicina da Universidade de São Paulo|
|Principal Investigator:||Maria Lucia H Katayama, PhD||Faculdade de Medicina da Universidade de São Paulo|